abrdn Life Sciences Investors (NYSE:HQL) Short Interest Update

abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 18,442 shares, a decline of 70.6% from the July 15th total of 62,733 shares. Based on an average daily volume of 177,512 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the company’s stock are short sold.

abrdn Life Sciences Investors Trading Up 0.1%

NYSE:HQL traded up $0.01 on Friday, hitting $21.16. The stock had a trading volume of 111,211 shares, compared to its average volume of 168,577. abrdn Life Sciences Investors has a 1 year low of $13.57 and a 1 year high of $21.42. The firm’s fifty day simple moving average is $19.36 and its two-hundred day simple moving average is $17.89.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $2.48 annualized dividend and a dividend yield of 11.7%.

Institutional Trading of abrdn Life Sciences Investors

Institutional investors and hedge funds have recently modified their holdings of the business. KPP Advisory Services LLC boosted its position in abrdn Life Sciences Investors by 2.7% in the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after purchasing an additional 660 shares during the last quarter. 180 Wealth Advisors LLC increased its position in shares of abrdn Life Sciences Investors by 2.2% during the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after purchasing an additional 3,271 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of abrdn Life Sciences Investors by 17.6% during the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock worth $387,000 after purchasing an additional 3,562 shares during the period. WNY Asset Management LLC bought a new stake in shares of abrdn Life Sciences Investors during the 1st quarter worth $239,000. Finally, Bank of America Corp DE boosted its holdings in shares of abrdn Life Sciences Investors by 8.6% in the 1st quarter. Bank of America Corp DE now owns 115,585 shares of the company’s stock worth $1,881,000 after buying an additional 9,145 shares during the last quarter. 32.21% of the stock is owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.